Net sales of Novo Nordisk by quarter 2021-2023
Net sales per quarter of Danish pharmaceutical company Novo Nordisk increased almost constantly in the provided period. The fourth quarter of 2023 set another record high reaching nearly 66 billion Danish kroner. This statistic shows Novo Nordisk's net sales per quarter between 2021 and 2023.
Shift change at big pharma's top
Novo Nordisk has been in the public's focus lately, mostly due to its diabetes and weight loss drug Ozempic/Wegovy. As a result, Novo Nordisk's share prices have increased massively, making it the world's third ranked pharmaceutical company based on market capitalization, topped only by Eli Lilly and Johnson & Johnson (which is not a pure play pharma company). As of October 2023, Novo Nordisk was valued at over 300 billion U.S. dollars, while Eli Lilly stood at almost half a trillion U.S. dollars.
Is 'semaglutide' the new superstar?
Novo Nordisk's highly valued products Ozempic, Rybelsus, and Wegovy are all based on semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Ozempic was approved in June 2017 in the U.S., as an injectable antidiabetic medication. In September 2019, a version for oral administration (Rybelsus) was approved. Finally, a high dosage version of the drug (Wegovy) was approved in June 2021, marketed as a weight loss/anti-obesity medication. Since overweight and obesity are huge problems in many (developed) countries, this product is believed to have very high market potential in the near future.
Shift change at big pharma's top
Novo Nordisk has been in the public's focus lately, mostly due to its diabetes and weight loss drug Ozempic/Wegovy. As a result, Novo Nordisk's share prices have increased massively, making it the world's third ranked pharmaceutical company based on market capitalization, topped only by Eli Lilly and Johnson & Johnson (which is not a pure play pharma company). As of October 2023, Novo Nordisk was valued at over 300 billion U.S. dollars, while Eli Lilly stood at almost half a trillion U.S. dollars.
Is 'semaglutide' the new superstar?
Novo Nordisk's highly valued products Ozempic, Rybelsus, and Wegovy are all based on semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Ozempic was approved in June 2017 in the U.S., as an injectable antidiabetic medication. In September 2019, a version for oral administration (Rybelsus) was approved. Finally, a high dosage version of the drug (Wegovy) was approved in June 2021, marketed as a weight loss/anti-obesity medication. Since overweight and obesity are huge problems in many (developed) countries, this product is believed to have very high market potential in the near future.
